EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Anna Dorothea WagnerHeike I GrabschMurielle MauerSandrine MarreaudCarmela CaballeroPeter Thuss-PatienceLothar MuellerAnnelie ElmeMarkus Hermann MoehlerUwe MartensYoon-Koo KangSun Young RhaAnnemieke CatsMasanori TokunagaFlorian LordickPublished in: BMC cancer (2019)
This article reports a health care intervention on human participants and was registered on July 10, 2014 under ClinicalTrials.gov identifier: NCT02205047 ; EudraCT: 2014-000722-38.
Keyphrases
- phase ii
- papillary thyroid
- locally advanced
- clinical trial
- healthcare
- squamous cell
- phase iii
- epidermal growth factor receptor
- open label
- randomized controlled trial
- squamous cell carcinoma
- study protocol
- patients undergoing
- cardiac surgery
- young adults
- acute kidney injury
- rectal cancer
- combination therapy
- tyrosine kinase
- chemotherapy induced